Neoprobe taps new VP

Gamma camera probe developer Neoprobe has appointed a new vice president of pharmaceutical research and clinical development, the Dublin, OH, company reported.

Frederick Cope, Ph.D., most recently served as assistant director for research and head of program research development for Ohio State University's Comprehensive Cancer Center, the James Cancer Hospital, and the Richard J. Solove Research Institute.

Neoprobe's proprietary radioactive tracing agent, Lymphoseek, is being developed for use with intraoperative lymphatic mapping (ILM). The agent is currently in a phase III, multicenter clinical trial for patients with breast cancer or melanoma, Neoprobe said.

Related Reading

Neoprobe completes financing, December 8, 2008

Neoprobe gets OK for Lymphoseek study, April 16, 2008

Neoprobe announces phase II Lymphoseek results, March 13, 2008

Neoprobe nets financing, December 27, 2007

Neoprobe extends agreement with Ethicon, December 20, 2007

Copyright © 2009

Page 1 of 434
Next Page